Pfizer looks for conditional EU authorization for COVID-19 drug
European Medicines Agency starts evaluating application for conditional marketing authorization for Paxlovid
BRUSSELS
The European Medicines Agency (EMA) said on Monday that it has begun evaluating an application by Pfizer for its anti-coronavirus drug Paxlovid.
“EMA has started evaluating an application for a conditional marketing authorization for the oral antiviral medicine Paxlovid,” the EU regulator said in a statement.
The statement said that the regulator could deliver its assessment within weeks since it had already carried out a preliminary review based on laboratory, animal, and clinical studies.
Following EMA’s recommendation, the European Commission would officially give the marketing authorization.
The medicine reduces the ability of the virus to multiply in the body.
By treating adults and adolescents with mild-to-moderate symptoms of COVID-19, the drug can lower the risk of developing severe illness and hospitalization.
Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. Please contact us for subscription options.
